Patents by Inventor Patrick J. Miller

Patrick J. Miller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8304521
    Abstract: Pax3, a member of the paired class homeodomain family of transcription factors and an essential protein for early skeletal muscle development, was shown to be phosphorylated in proliferating mouse primary myoblasts. Furthermore, Ser205, Ser201 and Ser209 were identified as the only sites of phosphorylation on Pax3 in proliferating mouse primary myoblasts. Phosphorylation of Ser205 was shown to be required for the efficient phosphorylation of Ser201 and/or Ser209. Site-specific antibodies were made to each of these three sites when phosphorylated. These three sites are also present and phosphorylated in the Pax3-FOXO1 fusion protein, and phosphorylation of these sites may play a role in ARMS. Thus, these new antibodies may be used in studying the regulation of nerve and muscle development and differentiation and in finding therapeutic solutions for certain disorders, including Waardenburg syndrome and childhood solid muscle tumor alveolar rhabdomyosarcoma (ARMS).
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: November 6, 2012
    Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventors: Andrew D. Hollenbach, Patrick J. Miller, Kevin N. Dietz
  • Publication number: 20090298083
    Abstract: Pax3, a member of the paired class homeodomain family of transcription factors and an essential protein for early skeletal muscle development, was shown to be phosphorylated in proliferating mouse primary myoblasts. Furthermore, Ser205, Ser201 and Ser209 were identified as the only sites of phosphorylation on Pax3 in proliferating mouse primary myoblasts. Phosphorylation of Ser205 was shown to be required for the efficient phosphorylation of Ser201 and/or Ser209. Site-specific antibodies were made to each of these three sites when phosphorylated. These three sites are also present and phosphorylated in the Pax3-FOXO1 fusion protein, and phosphorylation of these sites may play a role in ARMS. Thus, these new antibodies may be used in studying the regulation of nerve and muscle development and differentiation and in finding therapeutic solutions for certain disorders, including Waardenburg syndrome and childhood solid muscle tumor alveolar rhabdomyosarcoma (ARMS).
    Type: Application
    Filed: June 3, 2009
    Publication date: December 3, 2009
    Inventors: Andrew D. Hollenbach, Patrick J. Miller, Kevin N. Dietz
  • Patent number: 5401515
    Abstract: Aqueous coating compositions for forming elastomeric films around active cores (e.g., drugs) comprising a dispersion of pre-crosslinked polyorganosiloxane latex particles, colloidal silica particles, and a water-dispersible organic material (e.g., polyethylene glycol) are disclosed and claimed. The elastomeric films formed by the coating compositions are used to control the rate of release of an active agent in the cores into an aqueous environment. Methods of formulating the coating compositions and active cores coated with the coating compositions are also disclosed.
    Type: Grant
    Filed: January 28, 1994
    Date of Patent: March 28, 1995
    Assignee: Dow Corning Corporation
    Inventors: John T. Woodard, Martin C. Musolf, Patrick J. Miller
  • Patent number: 5358990
    Abstract: Aqueous coating compositions for forming elastomeric films around active cores (e.g., drugs) comprising a dispersion of pre-crosslinked polyorganosiloxane latex particles, colloidal silica particles, and a water-dispersible organic material (e.g., polyethylene glycol) are disclosed and claimed. The elastomeric films formed by the coating compositions are used to control the rate of release of an active agent in the cores into an aqueous environment. Methods of formulating the coating compositions and active cores coated with the coating compositions are also disclosed.
    Type: Grant
    Filed: February 11, 1993
    Date of Patent: October 25, 1994
    Assignee: Dow Corning Corporation
    Inventors: John T. Woodard, Martin C. Musolf, Patrick J. Miller
  • Patent number: 5310572
    Abstract: Aqueous coating compositions for forming elastomeric films around active cores (e.g., drugs) comprising a dispersion of pre-crosslinked polyorganosiloxane latex particles, colloidal silica particles, and a water-dispersible organic material (e.g., polyethylene glycol) are disclosed and claimed. The elastomeric films formed by the coating compositions are used to control the rate of release of an active agent in the cores into an aqueous environment. Methods of formulating the coating compositions and active cores coated with the coating compositions are also disclosed.
    Type: Grant
    Filed: August 31, 1992
    Date of Patent: May 10, 1994
    Assignee: Dow Corning Corporation
    Inventors: John T. Woodard, Martin C. Musolf, Patrick J. Miller
  • Patent number: 4882377
    Abstract: A pressure-adherent silicone elastomer composition comprising a homogeneous mixture of a silicone pressure sensitive adhesive composition, a crosslinkable silicone elastomer composition, and, optionally, a viscosity reducing agent. Specifically, the silicone pressure sensitive adhesive composition is a condensation product, having a plasticity of less than 200 mils, of a benzene-soluble resinous copolymer containing silicon-bonded hydroxyl radicals and consisting essentially of triorganosiloxy units of the formula R.sub.3 SiO.sub.1/2 and tetrafunctionalsiloxy units of the formula SiO.sub.4/2 in a ratio of about 0.6 to 0.9 triorganosiloxy units for each tetrafunctionalsiloxy unit present in the copolymer and a polydiorganosiloxane having a viscosity from 100 centipoise to 50,000 centipoise at 25.degree. C.
    Type: Grant
    Filed: September 21, 1988
    Date of Patent: November 21, 1989
    Assignee: Dow Corning Corporation
    Inventors: Randall P. Sweet, Patrick J. Miller, Virgil L. Metevia